Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Ja Min Byun, MD, PhD
Advertisement
Articles by Ja Min Byun, MD, PhD
Advertisement
Latest Updated Articles
What Stood Out at IMS 2026? 5 Myeloma Experts Weigh InOctober 2nd 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5